Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3622532 | 0.92 | CNR1 (1.00) | CNR1CNR2 | |
| SCHEMBL3615711 | 0.87 | CNR1 (0.82) | CNR1CNR2 | |
| SCHEMBL27642419 | 0.81 | CNR1 (0.57) | CNR1CNR2 | |
| SCHEMBL3626102 | 0.79 | CNR1 (0.65) | CNR1CNR2 | |
| SCHEMBL3625798 | 0.78 | CNR1 (0.75) | CNR1CNR2 | |
| SCHEMBL5365312 | 0.78 | CNR1 (0.74) | CNR1CNR2 | |
| SCHEMBL3627816 | 0.76 | CNR1 (0.72) | CNR1CNR2 | |
| SCHEMBL27642420 | 0.76 | CNR1 (0.50) | CNR1CNR2 | |
| SCHEMBL4412951 | 0.76 | CNR1 (0.65) | CNR1CNR2 | |
| SCHEMBL3627919 | 0.74 | CNR1 (0.49) | CNR1CNR2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7728141-B2 | Substituted naphthyridinone derivatives | MERCK SHARP & DOHME CORP. (US) | 2010-06-01 | — | — | US | disclosed |
| EP-1682550-B1 | SUBSTITUTED NAPHTHYRIDINONE DERIVATIVES | MERCK & CO INC (US) | 2009-12-23 | — | — | EP | disclosed |
| US-20070032517-A1 | Substituted naphthyridinone derivatives | MERCK SHARP & DOHME CORP. | 2007-02-08 | — | — | US | disclosed |
| EP-1682550-A4 | SUBSTITUTED NAPHTHYRIDINONE DERIVATIVES | MERCK & CO INC (US) | 2007-01-03 | — | — | EP | disclosed |
| CN-1875021-A | Substituted naphthyridinone derivatives | MERCK & CO INC (US) | 2006-12-06 | — | — | CN | disclosed |
| EP-1682550-A1 | SUBSTITUTED NAPHTHYRIDINONE DERIVATIVES | Merck & Co., Inc. (US) | 2006-07-26 | — | — | EP | disclosed |
| WO-2005047285-A1 | SUBSTITUTED NAPHTHYRIDINONE DERIVATIVES | MERCK & CO., INC. (US) | 2005-05-26 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070032517-A1 | Substituted naphthyridinone derivatives | CNR1, CNR2, MAG | CNR1 1/4885CNR2 2/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.